Dermatology

US consensus offers structured diagnostic and treatment algorithm for chronic hand eczema

This expert statement emphasizes that chronic hand eczema is multifactorial, heterogeneous, and lacks standardized classification and ICD-10 coding in the United States. It recommends thorough occupational, irritant, allergen, and atopic history plus detailed hand and wrist examination for diagnosis and subtype characterization. A multi-step management algorithm is proposed, beginning with trigger avoidance, barrier protection, emollients, and appropriate-potency topical corticosteroids. Topical delgocitinib is positioned as the only FDA-approved CHE therapy for patients inadequately controlled on, or unable to use, topical steroids. 1

As-needed ruxolitinib cream sustains control in mild–moderate atopic dermatitis with substantial off-treatment time

This pooled phase 3 analysis evaluated patients ≥12 years with mild–moderate atopic dermatitis treated with 1.5% ruxolitinib cream. After 8 weeks of twice-daily induction, 67.1% achieved IGA 0/1 before switching to as-needed treatment for up to 44 weeks. From week 8 onward, 80–90% of patients with IGA 0/1 at one visit maintained or improved their status at the next visit. Median time to disease worsening (IGA ≥2) during as-needed therapy was 36.1 weeks, and IGA 0/1 was rapidly recaptured with retreatment. 2

SGLT2 inhibitors linked to lower mortality and cardiorenal events in psoriasis with type 2 diabetes

This target-trial emulation compared SGLT2 inhibitors with DPP-4 inhibitors and GLP-1 receptor agonists in adults with psoriasis and type 2 diabetes. Among 8,799 matched SGLT2 versus DPP-4 initiators, SGLT2 use was associated with significantly lower all-cause mortality. SGLT2 therapy also reduced risks of emergency visits, acute kidney injury, chronic kidney disease, end-stage renal disease, and severe sepsis versus DPP-4 inhibitors. Compared with GLP-1 receptor agonists, SGLT2 inhibitors were associated with lower risks of asthma, depression, sleep disorders, and malignancies. 3

Dermatologic screening and mole mapping detect melanoma at thinner Breslow thickness

This retrospective cohort studied 475 melanomas diagnosed between 2017 and 2024, relating screening history and diagnostic methods to tumor stage. Patients screened within two years before diagnosis had more melanoma in situ and thinner invasive tumors than first-visit patients. In high-risk individuals, increasing visit frequency correlated with progressively lower tumor thickness compared with no screening. Digital mole mapping detected significantly thinner invasive melanomas than dermoscopy alone, particularly in high-risk patients. 4